Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR)

BACKGROUND: Anti-Her-2 treatment is successfully administered to Her-2 overexpressing breast cancer patients and significantly implicates upon their survival. Building on these promising results, anti-Her-2 treatment protocols were tested as an option for epithelial ovarian cancer (EOC) as well. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Heublein, Sabine, Vrekoussis, Thomas, Mayr, Doris, Friese, Klaus, Lenhard, Miriam, Jeschke, Udo, Dian, Darius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557169/
https://www.ncbi.nlm.nih.gov/pubmed/23339713
http://dx.doi.org/10.1186/1757-2215-6-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557169/
https://www.ncbi.nlm.nih.gov/pubmed/23339713
http://dx.doi.org/10.1186/1757-2215-6-6

Ejemplares similares